Header

UZH-Logo

Maintenance Infos

Konsensus Statement zur Prävention von Respiratory Syncytial Virus (RSV)-Infektionen mit dem humanisierten monoklonalen Antikörper Palivizumab (Synagis): Update 2016


Agyeman, P; Barazzone, C; Hammer, J; Heininger, U; Nadal, David; Pfammatter, J-P; Posfay-Barbe, K M; Pfister, R E (2017). Konsensus Statement zur Prävention von Respiratory Syncytial Virus (RSV)-Infektionen mit dem humanisierten monoklonalen Antikörper Palivizumab (Synagis): Update 2016. Paediatrica, 28(2):13-15.

Statistics

Downloads

33 downloads since deposited on 23 Aug 2017
33 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
Dewey Decimal Classification:610 Medicine & health
Language:German
Date:2017
Deposited On:23 Aug 2017 10:24
Last Modified:19 Mar 2018 08:30
Publisher:Schweizerische Gesellschaft für Pädiatrie
ISSN:1421-2277
OA Status:Green
Free access at:Official URL. An embargo period may apply.
Official URL:http://www.swiss-paediatrics.org/sites/default/files/13-15.pdf

Download

Download PDF  'Konsensus Statement zur Prävention von Respiratory Syncytial Virus (RSV)-Infektionen mit dem humanisierten monoklonalen Antikörper Palivizumab (Synagis): Update 2016'.
Preview
Content: Accepted Version
Language: German
Filetype: PDF
Size: 117kB